News >

NICE Cites Cost in Deciding Against Atezolizumab for Frontline Advanced Small Cell Lung Cancer

Gina Columbus @ginacolumbusonc
Published: Monday, Jan 06, 2020

lung cancer
The United Kingdom’s National Institute for Health and Care Excellence (NICE) did not recommend granting marketing authorization to atezolizumab (Tecentriq) in combination with carboplatin and etoposide for the treatment of patients with treatment-naïve extensive-stage small cell lung cancer (ES-SCLC).1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication